Latikafusp represents a distinct therapeutic method for treating certain cancers, particularly those involving aberrant anaplastic lymphoma kinase molecules. This compound functions as an inhibitor of truncated ALK molecules, demonstrating efficacy in laboratory studies and phase clinical assessments. Its process of effect offers a targeted method